These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 12814444)

  • 1. Central nervous system effects of moxonidine experimental sustained release formulation in patients with mild to moderate essential hypertension.
    Kemme MJ; vd Post JP; Schoemaker RC; Straub M; Cohen AF; van Gerven JM
    Br J Clin Pharmacol; 2003 Jun; 55(6):518-25. PubMed ID: 12814444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild-to-moderate essential hypertension.
    Küppers HE; Jäger BA; Luszick JH; Gräve MA; Hughes PR; Kaan EC
    J Hypertens; 1997 Jan; 15(1):93-7. PubMed ID: 9050976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic/pharmacodynamic assessment of tolerance to central nervous system effects of a 3 mg sustained release tablet of rilmenidine in hypertensive patients.
    van der Post JP; de Visser SJ; Schoemaker RC; Cohen AF; van Gerven JM
    J Psychopharmacol; 2004 Jun; 18(2):221-7. PubMed ID: 15260911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild to moderate essential hypertension.
    Prichard BN; Jäger BA; Luszick JH; Küster LJ; Verboom CN; Hughes PR; Sauermann W; Küppers HE
    Blood Press; 2002; 11(3):166-72. PubMed ID: 12126263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twenty-four-hour blood pressure profiles in patients with mild-to-moderate hypertension: moxonidine versus captopril.
    Kraft K; Vetter H
    J Cardiovasc Pharmacol; 1994; 24 Suppl 1():S29-33. PubMed ID: 7533224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension.
    Musini VM; Nazer M; Bassett K; Wright JM
    Cochrane Database Syst Rev; 2014 May; 2014(5):CD003824. PubMed ID: 24869750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Moxonidine vs. captopril in minor to intermediate hypertension. Double-blind study of effectiveness and tolerance].
    Lotti G; Gianrossi R
    Fortschr Med; 1993 Sep; 111(27):429-32. PubMed ID: 8225149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moxonidine improves insulin sensitivity in insulin-resistant hypertensives.
    Haenni A; Lithell H
    J Hypertens Suppl; 1999 Aug; 17(3):S29-35. PubMed ID: 10489096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moxonidine and cognitive function: interactions with moclobemide and lorazepam.
    Wesnes K; Simpson PM; Jansson B; Grahnén A; Weimann HJ; Küppers H
    Eur J Clin Pharmacol; 1997; 52(5):351-8. PubMed ID: 9272403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
    Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of moxonidine and cilazapril on microcirculation as assessed by finger nailfold capillaroscopy in mild-to-moderate hypertension.
    Martina B; Surber C; Jakobi C; Sponagel L; Gasser P
    Angiology; 1998 Nov; 49(11):897-901. PubMed ID: 9822045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concentration-effect relationships of two infusion rates of the imidazoline antihypertensive agent rilmenidine for blood pressure and development of side-effects in healthy subjects.
    de Visser SJ; van Gerven JM; Schoemaker RC; Cohen AF
    Br J Clin Pharmacol; 2001 May; 51(5):423-8. PubMed ID: 11421999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of chronic, sustained-release moxonidine therapy on clinical and neurohumoral status in patients with heart failure.
    Dickstein K; Manhenke C; Aarsland T; McNay J; Wiltse C; Wright T
    Int J Cardiol; 2000 Sep; 75(2-3):167-76; discussion 176-7. PubMed ID: 11077130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of moxonidine in elderly patients with resistant hypertension.
    Martin U; Hill C; O' Mahony D
    J Clin Pharm Ther; 2005 Oct; 30(5):433-7. PubMed ID: 16164488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of manual versus ambulatory blood pressure measurements with pharmacokinetic-pharmacodynamic modeling of antihypertensive compounds: application to moxonidine.
    Trocóniz IF; de Alwis DP; Tillmann C; Callies S; Mitchell M; Schaefer HG
    Clin Pharmacol Ther; 2000 Jul; 68(1):18-27. PubMed ID: 10945312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic action and pharmacokinetics of moxonidine after single oral administration in hypertension patients.
    Kirch W; Hutt HJ; Plänitz V
    J Clin Pharmacol; 1990 Dec; 30(12):1088-95. PubMed ID: 2273081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. General pharmacology of the novel centrally acting antihypertensive agent moxonidine.
    Armah BI; Hofferber E; Stenzel W
    Arzneimittelforschung; 1988 Oct; 38(10):1426-34. PubMed ID: 3196383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antihypertensive efficacy of a slow release nifedipine tablet formulation given once daily in patients with mild to moderate hypertension. A placebo-controlled, double-blind parallel-group trial.
    Harder S; Rietbrock S; Thürmann P
    Arzneimittelforschung; 1994 Feb; 44(2):133-6. PubMed ID: 8147945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.
    Prichard BN; Owens CW; Graham BR
    J Hum Hypertens; 1997 Aug; 11 Suppl 1():S29-45. PubMed ID: 9321737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. I1 imidazoline agonists. General clinical pharmacology of imidazoline receptors: implications for the treatment of the elderly.
    Prichard BN; Graham BR
    Drugs Aging; 2000 Aug; 17(2):133-59. PubMed ID: 10984201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.